Literature DB >> 3190179

Influence of storage and susceptibility test conditions on stability and activity of LY163892 and four other cephalosporins.

J H Jorgensen1, J S Redding, L A Maher.   

Abstract

A new carbacephem analog of cefaclor, LY163892, was examined along with four other cephalosporins for chemical stability and for antibacterial activity under a variety of susceptibility test conditions. LY163892 was found to be markedly more stable than cefaclor during storage at 4 and 35 degrees C in human serum, human urine, and various bacteriological media. Under these conditions, LY163892 demonstrated stability equal or superior to the stabilities of cephalexin, cephalothin, and cefuroxime. Broth and agar dilution susceptibility tests did not reveal significant differences in LY163892 activity in a variety of test media, although LY163892 MICs were somewhat higher in Mueller-Hinton chocolate agar or Trypticase soy broth (BBL Microbiology Systems, Cockeysville, Md.) than in other media. The activity of LY163892 against selected pathogens was only slightly influenced by the increased or decreased pH of the test medium, in a manner similar to that of the other cephalosporins tested. Thus, the carbacephem structure of LY163892 appears to represent a more stable cephalosporin than cefaclor, while retaining a similar antimicrobial spectrum.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3190179      PMCID: PMC175901          DOI: 10.1128/AAC.32.10.1477

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  5 in total

1.  Stability and blood level determinations of cefaclor, a new oral cephalosporin antibiotic.

Authors:  M A Foglesong; J W Lamb; J V Dietz
Journal:  Antimicrob Agents Chemother       Date:  1978-01       Impact factor: 5.191

2.  Summary of laboratory studies on the antibacterial activity of cefaclor.

Authors:  D A Preston
Journal:  Postgrad Med J       Date:  1979       Impact factor: 2.401

3.  In vitro susceptibilities of common pediatric pathogens to LY163892.

Authors:  S Shelton; J D Nelson
Journal:  Antimicrob Agents Chemother       Date:  1988-02       Impact factor: 5.191

4.  In vitro activities of LY163892, cefaclor, and cefuroxime.

Authors:  C C Knapp; J A Washington
Journal:  Antimicrob Agents Chemother       Date:  1988-01       Impact factor: 5.191

5.  Improved medium for antimicrobial susceptibility testing of Haemophilus influenzae.

Authors:  J H Jorgensen; J S Redding; L A Maher; A W Howell
Journal:  J Clin Microbiol       Date:  1987-11       Impact factor: 5.948

  5 in total
  6 in total

1.  Pharmaceutical properties of loracarbef: the remarkable solution stability of an oral 1-carba-1-dethiacephalosporin antibiotic.

Authors:  C E Pasini; J M Indelicato
Journal:  Pharm Res       Date:  1992-02       Impact factor: 4.200

2.  Antimicrobial resistance among respiratory isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae in the United States.

Authors:  J H Jorgensen; G V Doern; L A Maher; A W Howell; J S Redding
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

3.  Comparative in vitro activities of several new fluoroquinolones and beta-lactam antimicrobial agents against community isolates of Streptococcus pneumoniae.

Authors:  T Mazzulli; A E Simor; R Jaeger; S Fuller; D E Low
Journal:  Antimicrob Agents Chemother       Date:  1990-03       Impact factor: 5.191

4.  Loracarbef versus penicillin V in the treatment of streptococcal pharyngitis and tonsillitis.

Authors:  O Müller; Z Spirer; K Wettich
Journal:  Infection       Date:  1992 Sep-Oct       Impact factor: 3.553

5.  Comparison of loracarbef (LY163892) versus amoxicillin in the treatment of bronchopneumonia and lobar pneumonia.

Authors:  O Müller; K Wettich
Journal:  Infection       Date:  1992 May-Jun       Impact factor: 3.553

6.  Molecular basis of the efficacy of cefaclor against Haemophilus influenzae.

Authors:  M Picard; F Malouin
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.